Title:
TRICYCLIC KINASE INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2021/213460
Kind Code:
A1
Abstract:
The present invention belongs to the technical field of medicine, and specifically relates to a tricyclic DNA-PK kinase inhibitor compound represented by general formula (I), a pharmaceutically acceptable salt thereof or an isomer thereof, a pharmaceutical composition and preparation containing the compound, the pharmaceutically acceptable salt thereof or the isomer thereof, a method for preparing the compound, the pharmaceutically acceptable salt thereof or the isomer thereof, and a use of the compound, the pharmaceutically acceptable salt thereof or the isomer thereof.
More Like This:
| WO/2007/131020 | CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS |
| JP2013504543 | Ether derivatives of bicyclic heteroaryls |
| WO1999063936 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENDOTHELIN RECEPTORS |
Inventors:
LIU BIN (CN)
CHEN BO (CN)
CHEN BO (CN)
Application Number:
PCT/CN2021/088926
Publication Date:
October 28, 2021
Filing Date:
April 22, 2021
Export Citation:
Assignee:
SHANDONG XUANZHU PHARMA CO LTD (CN)
International Classes:
C07D519/00; A61K31/522; A61P35/00
Domestic Patent References:
| WO2018114999A1 | 2018-06-28 | |||
| WO2020238900A1 | 2020-12-03 | |||
| WO2019143678A1 | 2019-07-25 | |||
| WO2019143675A1 | 2019-07-25 |
Attorney, Agent or Firm:
CCPIT PATENT AND TRADEMARK LAW OFFICE (CN)
Download PDF:
Previous Patent: 3D PRINTED ORTHOPEDIC INSOLE FOR HALLUX VALGUS
Next Patent: VEHICLE INTERIOR COMPONENT
Next Patent: VEHICLE INTERIOR COMPONENT